Enbridge (NYSE:ENB – Get Free Report) (TSE:ENB) was downgraded by equities researchers at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research report issued on Monday, Marketbeat reports.
Enbridge Stock Up 1.3 %
ENB opened at $41.14 on Monday. The firm’s 50 day simple moving average is $39.43 and its two-hundred day simple moving average is $37.06. The company has a market capitalization of $87.79 billion, a PE ratio of 20.88, a PEG ratio of 3.93 and a beta of 0.94. Enbridge has a 1-year low of $31.03 and a 1-year high of $41.22. The company has a current ratio of 0.77, a quick ratio of 0.68 and a debt-to-equity ratio of 1.34.
Enbridge (NYSE:ENB – Get Free Report) (TSE:ENB) last released its earnings results on Friday, August 2nd. The pipeline company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.13. The company had revenue of $8.29 billion for the quarter, compared to the consensus estimate of $4.28 billion. Enbridge had a return on equity of 10.07% and a net margin of 13.31%. During the same period in the previous year, the business earned $0.51 earnings per share. As a group, equities analysts forecast that Enbridge will post 2.08 EPS for the current year.
Hedge Funds Weigh In On Enbridge
Enbridge Company Profile
Enbridge Inc, together with its subsidiaries, operates as an energy infrastructure company. The company operates through five segments: Liquids Pipelines, Gas Transmission and Midstream, Gas Distribution and Storage, Renewable Power Generation, and Energy Services. The Liquids Pipelines segment operates pipelines and related terminals to transport various grades of crude oil and other liquid hydrocarbons in Canada and the United States.
Further Reading
- Five stocks we like better than Enbridge
- Buy P&G Now, Before It Sets A New All-Time High
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Profitably Trade Stocks at 52-Week Highs
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Enbridge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enbridge and related companies with MarketBeat.com's FREE daily email newsletter.